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Abstract
As a cause of community-acquired infections, extended-spectrum b-lactamase (ESBL)-producing Escherichia coli constitute an emerging
public-health concern. Few data on the molecular epidemiology of ESBL-producing E. coli isolates from pets are available in China.
Detection and characterization of ESBL genes (blaCTX-M, blaSHV and blaTEM) was conducted among 240 E. coli isolates recovered from
healthy and sick pets in South China from 2007 to 2008. The clonal relatedness of ESBL-producing E. coli isolates was assessed by
pulsed ﬁeld gel electrophoresis. ESBL-encoding genes were identiﬁed in 97 (40.4%) of the 240 isolates and 96 (40.0%) of them harbored
CTX-M. The most common CTX-M types were CTX-M-14 (n = 45) and CTX-M-55 (n = 24). The recently reported CTX-M-64 was
identiﬁed in three isolates. Isolates producing CTX-M-27, -15, -65, -24, -3 and -9 were also identiﬁed. Ten isolates carried two or three
CTX-M types, with the combination of CTX-M-14 and CTX-M-55 being the most frequent (n = 6). ISEcp1 was identiﬁed in the
upstream region of 93 out of the 107 blaCTX-M genes (86.9%). The sequence of the spacer region (45 bp) between ISEcp1 and the start
codon of all blaCTX-M-55 genes (except four) was identical to that of blaCTX-M-64. No major clonal relatedness was observed among these
CTX-M producers. It is suggested that the horizontal transfer of blaCTX-M genes, mediated by mobile elements, contributes to their dis-
semination among E. coli isolates from pets. Our ﬁnding of high prevalence of ESBL in E. coli of companion animal origin illustrates the
importance of molecular surveillance in tracking CTX-M-producing E. coli strains in pets.
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Introduction
The Gram-negative bacterium Escherichia coli is a common
intestinal microorganism of humans and animals, with the
capability of acquiring and preserving transferable resistance
genes found in other organisms and the environment. In
addition, E. coli is also an important pathogen causing a vari-
ety of illnesses, including urinary and gastrointestinal infec-
tions and septicaemia. For the treatment of these infections,
b-lactams including cephalosporins are frequently used in
human and veterinary medicine [1]. The major mechanisms
of resistance to oxyimino-cephalosporins in E. coli rely on
the production of extended-spectrum b-lactamases (ESBLs)
[2]. In the past few years, a rapid dissemination of E. coli iso-
lates producing ESBLs has been reported in many parts of
the world and CTX-M type enzymes have become the most
dominant ESBLs [3,4]. Of particular concern is the emer-
gence and dissemination of CTX-M family ESBLs among
E. coli within the community [5]. The CTX-M family is com-
posed of more than 80 heterogeneous ESBLs and can be
divided into ﬁve different groups (CTX-M-1, M-2, M-8, M-9
and M-25) based on amino acid sequence similarities. Within
each group, ESBLs share greater than 90% sequence identity
[3,4]. Recently, a new type of CTX-M enzyme, CTX-M-64,
that might be a chimera of CTX-M-15 and CTX-M-14 family
ESBLs, was identiﬁed in Japan, suggesting a new mechanism
of the evolution of CTX-M type ESBLs [6].
ESBLs are commonly detected in human clinical isolates.
Recent reports of the detection of ESBLs in bacterial isolates
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from animals have raised concern regarding the co-transfer
of ESBL genes between human and animal isolates [7]. Con-
sidering the shared environment of humans and pets and the
close contact between them, companion animals could be
potential sources of ESBL-producing E. coli isolates causing
community-acquired infections. In the present study, the
prevalence of ESBLs among E. coli isolates from companion
animals and the phenotype and genotype of ESBLs were
characterized to provide useful information about the epide-
miology and evolution of ESBLs in bacteria.
Materials and Methods
Bacterial isolates
A total of 240 E. coli isolates were obtained from faecal or
clinical samples of healthy (i.e. pets admitted to hospitals for
vaccination or for sale) and diseased dogs and cats (for diag-
nostic investigation) in eight animal hospitals and one pet
shop in Guangdong Province during November 2007 and
June 2008. Bacterial strains were identiﬁed using classical bio-
chemical methods and Microlog, release 4.2 (Biolog, Hay-
ward, CA, USA).
Antimicrobial susceptibility testing and ESBL conﬁrmation
Antimicrobial susceptibility was determined using the agar dilu-
tion and disk diffusion methods and interpreted according to
the CLSI recommendations [8,9]. E. coli ATCC25922 was used
as quality control strain in antimicrobial susceptibility testing.
Production of ESBLs in the isolates was determined with the
phenotypic conﬁrmatory test using both cefotaxime and ceft-
azidime, alone and in combination with clavulanic acid [9].
Detection of b-lactamase genes
PCR ampliﬁcation of blaCTX-M, blaTEM and blaSHV genes was
carried out for all ESBL-producing isolates using ExTaq DNA
polymerase (Takara, Dalian, China) and primers as previously
described [10]. Puriﬁed PCR products were directly
sequenced from both ends or cloned in pMD18-T and then
sequenced. The DNA sequences and deduced amino acid
sequences were compared, using BLAST, with sequences
available at GenBank and also compared with sequences at
Lahey Clinic (available at http://www.lahey.org/studies/
webt.html) to identify the subtypes of b-lactamase genes.
Analysis of the up- and downstream regions of blaCTX-M
type genes
Analysis of the blaCTX-M upstream regions was performed
using PCR with forward primers located in ISEcp1 (ISEcp1-F:
5¢-CTA TCC GTA CAA GGG AGT GT-3¢) or ISCR1 (CR1-F:
5¢-GTC AAT CGC CCA CTC AAA C-3¢), together with
reverse primers for group 1 (M1-R: 5¢-CCA TTG CCC GAG
GTG AAG-3¢) and group 9 CTX-M genes (M9-R: 5¢-CGG
CGT GGT GGT GTC TCT-3¢). The downstream regions of
blaCTX-M genes was investigated by PCR ampliﬁcation with the
CTX-M forward and reverse primers speciﬁc for orf477 (5¢-
CAG CGG AAG GAG AAC CAG-3¢) or IS903 (5¢-TTT CCA
CTC GCC TTC ACC-3¢). PCR products were puriﬁed and
subjected to bidirectional DNA sequencing. New CTX-M
sequences were deposited into the GenBank database and
assigned accession numbers GQ300937, GQ300938,
GQ456156, GQ456157, GQ456158 and GQ456159.
Conjugation experiments
The transfer of blaCTX-M between bacteria was assessed by
conjugation experiments using the ﬁlter method, as described
elsewhere [11]. Brieﬂy, the donor bacteria and the recipient,
streptomycin-resistant E. coli C600, were grown in tryptic soy
broth to logarithmic phase, mixed at a 1 : 4 ratio (v/v), col-
lected on a ﬁlter and incubated at 37C for 20 h. Transconju-
gants were selected on MacConkey agar containing
cefotaxime (2 mg/L) and streptomycin (1000 mg/L). Selected
transconjugants were further characterized in terms of their
antimicrobial susceptibility, ESBL phenotype and the presence
of blaCTX-M genes. The PCR identiﬁcation of blaCTX-M-64 in
transconjugants was conducted with the forward primer for
CTX-M-1 group genes and the reverse primer (M9-R) located
in the central region of the CTX-M-9 group genes.
Epidemiological typing
The ESBL-producing E. coli isolates were characterized by
pulsed ﬁeld gel electrophoresis (PFGE) using the CHEF-MAP-
PER System (Bio-Rad Laboratories, Hercules, CA, USA) as
described by Gautom [12]. Brieﬂy, the chromosomal DNA
of E. coli isolates was isolated and the plugs were subjected
to digestion with XbaI for 16 h at 37C. Electrophoresis was
carried out at 6.0 V/cm for 22 h, with an angle of 120º at
14C. The pulse time was increased from 0.5 to 60 s. A bac-
teriophage lambda DNA ladder consisting of 48.5-kb concat-
emers was used as a size marker. Gels were then stained in
ethidium bromide (1.0 mg/L). The results were interpreted
according to the criteria of Tenover et al. [13].
Results
A total of 240 E. coli were isolated from 185 dogs and 55
cats, with 226 (94.2%) animals from private owners (92 of
them were healthy pets admitted to hospitals for vaccination
and 134 were sick pets) and the remaining 14 healthy pets
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originating from one pet store. Approximately 93.0% of the
samples were from faeces and the rest were from nasal
mucus, wound swabs or other sources. Ninety-nine (41.3%)
of the 240 E. coli isolates were conﬁrmed to produce ESBLs
using the double-disk synergy test. The sample sources of
ESBL producers were: 88 from faeces, seven from nasal
mucus, and four from swabs (wound, skin and pharynx). The
ESBL producer rate was 54.5% (73/134) among isolates from
sick animals, and signiﬁcantly higher than among isolates from
healthy animals (24.5%; 26/106) (v2 = 19.504, p <0.01).
Ninety-eight percent (97/99) of the isolates harbored one
or more of the genes from the three families of TEM, SHV
and CTX-M, whereas two isolates failed to show the pres-
ence of such genes, suggesting that these two isolates have
(an)other ESBL-encoding gene(s) not detected with our
primers, which need further investigation. CTX-M type genes
were shown to be dominant in these isolates and 96 isolates
carried one or more CTX-M genes. The most common
CTX-M type was CTX-M-14 (n = 45), followed by CTX-M-
55 (n = 24), CTX-M-27 (n = 8), CTX-M-24 (n = 8), CTX-M-
15 (n = 6), CTX-M-65 (n = 6), CTX-M-3 (n = 5), CTX-M-64
(n = 3) and CTX-M-9 (n = 2). More than one type of CTX-
M type gene was identiﬁed in ten isolates and their combina-
tions were triple (CTX-M-55, -64, -14) in one isolate, and
double [CTX-M-55 and -14 (n = 6), CTX-M-55 and -65
(n = 1), CTX-M-55 and -9 (n = 1) and CTX-M-64 and -14
(n = 1)] in nine isolates (Table 1). In addition to the CTX-M
type genes, one E. coli isolate was positive for blaSHV-12 and
one carried both blaSHV-12 and blaCTX-M-9. A variant of
blaCTX-M-14, blaCTX-M-14b, which differs from blaCTX-M-14 at
three nucleotide positions (A372G, G570A, G702A) was
found in two E. coli isolates. Fifty-three isolates were positive
for blaTEM, and all were found to be blaTEM-1 by sequencing.
Analyses of antimicrobial susceptibility patterns of isolates
carrying CTX-M-1 subgroup (CTX-M-3, -15, -55 and -64)
and CTX-M-9 subgroup genes (CTX-M-14, 24, 27, 65), and
isolates producing more than one ESBL are shown in
Table 2. The isolates that carried CTX-M-1 subgroup genes
showed signiﬁcantly reduced susceptibilities to ceftazidime
compared to the CTX-M-9 subgroup (v2 = 26.58573,
p <0.01) but, interestingly, isolates carrying CTX-M-9 sub-
group genes alone showed signiﬁcantly reduced susceptibili-
ties to amikacin (v2 = 5.0073, p 0.014).
Chromosomal DNAs of 93 isolates were available for
PFGE typing. Banding patterns were not obtained from four
ESBL-producing E. coli isolates because their DNAs were
consistently autodigested. Based on CTX-M types, all clus-
ters according to PFGE proﬁles of CTX-M-producing E. coli
are shown in Table 1. The results reveal that a majority of
isolates showed unique, unrelated PFGE proﬁles and
were unlikely to be considered the cause of an epidemic.
However, among the three CTX-M-64-producing E. coli
isolates, two were clonally related.
Table 3 shows the genetic structure up- and downstream of
the blaCTX-M type genes detected among ESBL-positive isolates
in the present study. The ISEcp1-like and ISCR1 elements were
located upstream of 93 (86.9%) and one (blaCTX-M-9) of the
107 blaCTX-M genes, respectively. PCR ampliﬁcation of ISEcp1-
like elements and ISCR1 were negative for other blaCTX-M
genes. orf477 and IS903 were detected downstream of most
blaCTX-M-1 group and blaCTX-M-9 group genes respectively.
Nucleotide sequence analysis of the upstream region of
blaCTX-M type genes revealed that the spacer region between
the right inverted repeat (IRR) and blaCTX-M were found to
be 42–127 bp. All of the CTX-M-9 group genes (except
CTX-M-9) were located 42 up downstream of ISEcp1. A
127-bp intergenic region was found upstream of four blaCTX-
M-3 genes but, in the case of one blaCTX-M-3 gene, a 117-bp
intergenic region was found. The blaCTX-M-15 genes were
characterized by a 48-bp intergenic region, whereas all
blaCTX-M-55 (except four) and blaCTX-M-64 genes were charac-
terized by a 45-bp intergenic region.
The conjugation experiments were conducted for 96 CTX-
M-producing isolates to determine the transferability of
blaCTX-M. The results obtained indicated that the cefotaxime
resistance trait from 54 CTX-M-producing strains could be
transferred to the recipient strain, and transconjugants were
positive for blaCTX-M, suggesting that the blaCTX-M type genes
could well be located on conjugative plasmids and transferred
to other bacteria through conjugation. Two transconjugants
carrying different blaCTX-M genes, (blaCTX-M-64 and blaCTX-M-55,
respectively) were obtained from the E. coli isolate 096
(Table 1). By contrast to the donor strains, the transconju-
gants of CTX-M-1 subgroup genes remained susceptible to
ciproﬂoxacin, gentamicin, chloramphenicol and tetracycline,
suggesting the corresponding resistance mechanisms are not
transferable and located at a distance from the plasmid carry-
ing the CTX-M-1 group genes. However, unlike the resistance
in the CTX-M-1 subgroup transconjugants, non-b-lactam (i.e.
amikacin and chloramphenicol) resistance was cotransferred
with CTX-M-9 subgroup genes (Table 1), which is consistent
with the antimicrobial susceptibility of their donors in that
CTX-M-9 subgroup producers were more frequently resistant
to these antimicrobials than CTX-M-1 group producers.
Discussion
ESBL-producing E. coli, particularly those producing CTX-M
type ESBLs, are commonly associated with hospital- or
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community-related infection in humans [2,4]. Recently, ESBLs
have also been reported in Enterobacteriaceae isolated from
companion animals in some countries [14–16]. In China, only
ceftiofur-resistant Enterobacteriaceae isolated from companion
animals have been reported [17]. In the present study, we
provide the ﬁrst report of the surveillance of ESBL-gene dis-
semination in E. coli isolates from healthy and sick companion
animals in China.
Approximately 41.3% of the isolates screened were ESBL
producers, which is very similar to that found in human clini-
cal isolates from Guangzhou (39.5%) but somewhat lower
than in isolates from China as a whole (55%) [18]. However,
this percentage is much higher than that in isolates from
food animals in China [10,19] and companion animals in
other countries [15,16]. Only 3.3% and 11.0% of E. coli iso-
lates from food animals were ESBL-positive in 2003–2005
TABLE 1. Characteristics of isolates with extended-spectrum b-lactamase genes
blaCTX-M type
a
PFGE typeb
(number of
isolates) Isolatec
Origind
(number
of isolates)
Isolation
date
Hospital
(number
of isolates) Resistance phenotypee
CTX-M-3 (n = 5) 3NR 210, 225, 916 Cat, Dog, Cat 2008.2-2008.4 Y, F, F CTX GEN (CHL) TET (CIP)
3NT 153, 110 Cat, Dog 2008.1 Y CTX GEN AMK TET CIP
CTX-M-15 (n = 6) 15A (2) 108, 081 Dog 2007.11-2008.5 Z CTX CAZ GEN (AMI CHL FLR) TET CIP
15NR (4) 127 Dog 2008.1 F CTX CAZ GEN AMK CHL TET CIP
124, f57, 525 Dog, Dog, Cat 2007.11-2008.7 Z, Z, T CTX CAZ GEN (AMK) CHL (FLR) TET CIP
CTX-M-55 (n = 15) 55A (2) 02R, 424 Dog 2008. 2-2008.4 F CTX CAZ GEN AMK CHL FLR TET CIP
55NR (12) 122, 129, 160, 212,
312, 066, 107, 203
Dog (6), Dog, Cat 2007.11-2008.5 Z (3), F (2),
Y (2)
CTX CAZ (GEN CHL FLR) TET (CIP)
226, 061, 104, 138 Dog (3), Dog 2007.11-2008. 5 F, Z, Z, F CTX CAZ GEN (AMK CHL) TET (CIP)
55NT 410 Dog 2008.4 Z CTX CAZ TET CIP
CTX-M-64 64A hf2 Dog 2008.6 T CTX CAZ TET
CTX-M-64, -55, -14 64B1 096 Cat 2008.5 Y CTX CAZ FOX GEN AMK TET CIP
CTX-M-64, -14 64B2 218 Dog 2008.2 F CTX CAZ FOX TET CIP
CTX-M-55,-14 (n = 6) 55B (2) 120, 124 Dog 2008.1 F CTX CAZ GEN AMK CHL TET CIP
55NR (4) 304, 408, 313, 132 Dog 2008.3-2008.4 Z (3), F CTX CAZ (FOX GEN AMK) CHL TET CIP
CTX-M-65, -55 65A 143 Dog 2008.1 F CTX CAZ GEN AMK CHL TET
CTX-M-9, -55 9A 069 Dog 2008.5 Z CTX CAZ FOX GEN AMK TET CIP
CTX-M-9, SHV-12 9B 111 Dog 2008.1 Y CTX CAZ FOX GEN AMK CHL TET CIP
CTX-M-24a (n = 7) 24A (2) 308, 201 Dog 2008. 2, 3 F, Z CTX (CAZ FOX) GEN AMK CHL TET CIP
24B1 (2) 117, 404 Cat, Dog 2008.5, 4 Shop, Z CTX (CHL TET) (CIP)
24B2 118 Cat 2008.5 Shop CTX
24C 114 Dog 2008.1 F CTX GEN AMK CHL TET CIP
24D 146 Dog 2008.1 F CTX CAZ FOX GEN AMK TET CIP
CTX-M-24e 24Df 113 Cat 2008.5 Shop CTX CHL TET
CTX-M-27 (n = 8) 27NR (8) 109 Dog 2008. 1.18 Y CTX CAZ FOX GEN AMK CHL FLR CIP
SS6, 518 Dog, Dog 2008.1-2008.5 F, Z CTX CAZ GEN AMK (CHL) TET CIP
105, 252 Dog, Dog 2008. 1-2008.4 Y, Z CTX GEN AMK (CHL) TET (CIP)
303, 830, 202 Dog 2007.12-2008.3 Z CTX (CAZ) GEN AMK (CHL FLR TET) CIP
CTX-M-65 (n = 5) 65A 084 Cat 2008.5.8 Z CTX GEN AMK CHL TET CIP
65B1 181 Dog 2008.5.18 Z CTX GEN CHL FLR CIP
65B2 429 Cat 2008.4.29 C CTX GEN AMK CHL TET CIP
65NR 233, 409 Dog 2008.2-2008.3 F, Z CTX GEN AMK CHL (FLR) TET CIP
CTX-M-14 (n = 35) 14A1 083 Dog 2008.5, Z CTX GEN AMK CHL TET CIP
14A2 (3) f29, 301, 134 Cat, Dog, Dog 2008.1-2008.3 Y, Z, F CTX (GEN AMK CHL TET CIP)
14B (2) 309, 228 Dog 2008. 3, 2 Z, F CTX GEN AMK (CHL FLR TET) CIP
14C1 (2) 1201, 426 Dog, Dog 2007.11, 2008.4 Z CTX GEN AMK (CHL FLR TET) CIP
14C2 155 Dog 2008.1 A CTX GEN TET CIP
14NR (25) 1111, 112 Dog 2007.11-2008.1 Z, Y CTX GEN AMK CHL FLR TET CIP
13D, 116, 157 Dog, Dog, Dog 2008.1 F, F, A CTX GEN AMK (CHL FLR TET) CIP
128 Dog 2007.11 Z CTX GEN CHL FLR TET CIP
0141, 429, Dog 2008.1-2008.4 F CTX (FOX) GEN CHL (FLR) TET CIP
145, 525 Cat, Dog 2008.1-2008.5 F, Z CTX (FOX) GEN (AMK) CHL FLR TET CIP
SS3, 158, 1120 Dog, Dog, Dog 2007.11-2008.1 Y, A, Z CTX (GEN AMK CHL FLR TET) CIP
1129, 1201, 0115,
0154, 101, 102,
8304, 204, 305R,
311, 403, 5083,
184
Dog (8), Dog (5) 2007.11-2008.5 Z (8), F (2), A
(2), Y (2)
CTX (CAZ FOX GEN AMK CHL FLR TET CIP)
CTX-M-14b (n = 2) 14D 106, 08D Dog 2008.1 Y CTX GEN AMK CHL FLR TET CIP
SHV-12 NA Tfs Dog 2008.5 T GEN CIP
CTX, cefotaxime; CAZ, ceftazidime; FOX, cefoxitin; GEN, gentamicin; AMK, amikacin; CHL, chloramphenicol; FLR, ﬂorfenicol; TET, tetracycline; CIP, ciproﬂoxacin.
aThe extended-spectrum b-lactamase genes (ESBL) genes that were transferred to a recipient by conjugation are underlined.
bPatterns that differed by fewer than six bands were considered to represent subtypes within the main group (e.g., 14A1, 14A2). Patterns that differed from pattern 14A by
six or more bands were considered to represent different strains. NT, isolates did not generate DNA bands by the pulsed ﬁeld gel electrophoresis (PFGE) method used in
this study. NA, not applicable. 14NR, isolates with patterns that differ from 14A, 14B, 14C and each other by six or more bands. NA, not applicable.
cIsolates from which the ESBL gene was transferred to a recipient by conjugation are underlined.
dHealthy animals are in bold.
eIsolates were not susceptible according to National Committee on Clinical Laboratory Standards/CLSI guidelines. The criterium for ﬂorfenicol resistance is MIC ‡16 mg/L.
fResistance phenotypes transferred to recipient by conjugation are underlined. A variable presence or transferability of the resistance phenotype is indicated by parentheses.
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and 2007, respectively [10,19]. This may be a result of the
use of cephalosporins as common treatment for companion
animals; half of the diseased animals in the present study
have been treated with cephalosporins within 12 months
prior to sampling (data not shown). This is also consistent
with the fact that approximately 54.5% of the isolates from
sick animals carried ESBL genes, which is signiﬁcantly higher
than the corresponding 24.5% in healthy companion animals.
The CTX-M family was shown to have become dominant
(98%) in ESBL-producing companion animal isolates in the
present study, consistent with other reports concerning
human clinical isolates (76.8%) in China in which the CTX-
M-9 group accounts for the most prevalent gene types
(64.4%) [20,21]. Nine CTX-M types of speciﬁc ESBLs were
detected in E. coli isolates in the present study. The most
predominant ESBL was CTX-M-14 (45.0%), which is similar
to reports of human isolates in China [20,21]. CTX-M-55
of was also found to be prevalent (24.2%) in the present
study.
CTX-M-55 is a derivative of CTX-M-15 with enhanced
activity against ceftazidime and was ﬁrst identiﬁed in E. coli
and Klebsiella pneumoniae isolates in Thailand in 2007 [22].
CTX-M-55 has recently also been detected in other coun-
tries [23–25]. Most interestingly, subsequent to the ﬁrst dis-
covery of a novel CTX-M-64 in a Shigella sonnei isolate from
Japan [6], we detected CTX-M-64 in three E. coli isolates
from pets. Further research is needed to understand the
mechanism(s) of the development of this novel type of ESBL.
ISEcp1 is frequently found in the upstream region of
blaCTX-M type genes and plays an important role in blaCTX-M
expression and gene transfer [11,26,27]. In agreement with
previous studies [11,28], ISEcp1 was detected 42 bp
upstream of CTX-M-9 group (CTX-M-14, -24, -27 and -65)
genes and this is the ﬁrst time that ISEcp1 was identiﬁed
upstream of blaCTX-M-65.
For the CTX-M-1group of bla genes, consistent with other
studies, a 48-bp sequence, previously called the W sequence,
was detected between blaCTX-M-15 and ISEcp1 [11,28],
whereas a 45-bp spacer sequence has been identiﬁed in 18
of 22 blaCTX-M-55 copies, as well as in other bla genes such
as blaCTX-M-64 [6], blaCTX-M-79 (GenBank accession no.
FJ169498) and blaCTX-M-82 (GenBank accession number
DQ256091). Interestingly, both CTX-M-79 and CTX-M-82
were originally and recently reported from China [21,29]. In
the remaining four isolates, a 48-bp W sequence was
detected upstream of blaCTX-M-55, which was the same as
that described in isolates from Thailand and the UK
[22,23,28]. PFGE analysis showed very diverse patterns in
these blaCTX-M-positive E. coli isolates and suggested that the
high prevalence of blaCTX-M in E. coli is a result of horizontal
transfer of ESBL genes among bacteria instead of the pan-
demic spread of single clones.
The present study revealed that more than 60% of the
isolates carrying CTX-M-9 subgroup genes showed reduced
susceptibilities to amikacin, a transferable trait (data not
shown).
A recent study reported the co-localization of blaCTX-M-14
and rmtB on a broad-host-range IncA/C plasmid [30]. The
association of different resistance markers on the same plas-
mid can also promote the spread of ESBLs by co-selection.
Approximately 30% of the diseased animals in the present
study had been treated with amikacin (data not shown);
thus, amikacin might have positively selected for the ESBL
producers.
In conclusion, a surprisingly high prevalence of ESBL pro-
ducers was detected in E. coli isolates from companion
TABLE 3. Analysis of the genetic structure upstream and
downstream of the blaCTX-M type genes
Type of blaCTX-M
Number of
isolates
Size of the
intergenic
spacer region
between ISEcp1
and blaCTX-M (bp)
Number of
isolates
ISCR1 ISEcp1 orf477 IS903
CTX-M-3 (n = 5) 0 4
1
127
114
5 NA
CTX-M-15 (n = 6) 0 5 48 6 NA
CTX-M-55 (n = 24) 0 18
4
45
48
22 NA
CTX-M-64 (n = 3) 0 3 45 3 NA
CTX-M-14 (n = 45) 0 37 42 NA 28
CTX-M-24 (n = 8) 0 8 42 NA 6
CTX-M-27 (n = 8) 0 7 42 NA 7
CTX-M-65 (n = 6) 0 6 42 NA 5
CTX-M-9 (n = 2) 1 0 NA NA 0
NA, not applicable.
TABLE 2. Antimicrobial susceptibilities of isolates producing
extended-spectrum b-lactamase genes
Antimicrobial
Susceptibility (%)
CTX-M-1a
group
(n = 27)
CTX-M-9
group
(n = 58)
More than
one ESBL
gene (n = 11)
Total
(n = 99)
Cefotaxime 0 0 0 1.0
Ceftazidime 22.2 82.8 0 57.6
Cefoxitin 100.0 87.9 33.3 84.8
Amoxicillin–clavulanic acid 61.5 67.2 33.3 61.6
Imipenem 100.0 100.0 100.0 100.0
Gentamicin 14.8 17.2 8.3 15.2
Amikacin 66.7 38.3 25.0 47.5
Ciproﬂoxacin 18.5 19.0 16.7 20.2
Chloramphenicol 40.7 29.3 16.7 32.3
Florfenicol 66.7 60.3 66.7 73.7
Tetracycline 0 6.9 0 6.1
aAs blaCTX-M-64 was ampliﬁed with CTX-M-1 group-speciﬁc primers targeting
the 5¢ and 3¢ ends of blaCTX-M, it was included in CTX-M-1 group in the present
study.
The data with signiﬁcant difference between different groups were bold.
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animals in China, with CTX-M type enzymes being most pre-
dominant. It is necessary to examine the factors that contrib-
uted to their selection and dissemination. This is the ﬁrst
report of the emergence of CTX-M-64 in China and in ani-
mals. The clinical signiﬁcance of the ﬁnding that CTX-M-55
and CTX-M-14 were simultaneously detected in six isolates
is yet to be ascertained. The present study extends our
knowledge of the prevalence and evolution of ESBLs in both
China and throughout the world. Attention should be drawn
to this serious situation of ESBL-producing E. coli as well as
other bacteria in companion animals.
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